ArticleVaccines2022
Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi Population.
Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Impact of COVID-19 vaccination and vaccine type on morbidity and mortality in hospitalized patients: a retrospective cohort study in Egypt.Frontiers in microbiology · 2026Article
- Comparison of the immunogenicity and safety among COVID-19 vaccines ChadOx-1, CoronaVac and BNT162b2 in systemic lupus erythematosus (SLE) patients: a prospective cohort.Advances in rheumatology (London, England) · 2025Article
- Article
- Longitudinal evaluation of T-cell responses to Pfizer-BioNTech and Janssen SARS-CoV-2 vaccines as boosters in Ghanaian adults.Frontiers in immunology · 2025Article
- Comparison of SARS-CoV-2 immune responses following vaccination with Comirnaty (Pfizer) and Vaxzevria (AstraZeneca) in healthy individuals with or without prior SARS-CoV-2 infection.Frontiers in immunology · 2025Article
- Review
- Article
- Article
- Comparison of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Antibody Response by Different Vaccine Combinations.Journal of clinical practice and research · 2024Article
- Antibody longevity and waning following COVID-19 vaccination in a 1-year longitudinal cohort in Bangladesh.Scientific reports · 2024Article
- Serosurveillance among urban slum and non-slum populations immunized with COVID-19 vaccines in Bangladesh.Epidemiology and infection · 2024Article
- Article
- Article
- Association of fat-soluble vitamins (A, D, and E) status with humoral immune response to COVID-19 inactivated vaccination.Frontiers in nutrition · 2023Article
- Antibody response to different COVID-19 vaccines among the migrant workers of Bangladesh.Frontiers in immunology · 2023Article
- Evaluation of Seroconversion Rate Following SARS COV 2 Vaccination in Health Care Workers at Shahid Beheshti University of Medical Sciences.Avicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe adaptive immune response is a crucial component of the protective immunity against SARS-CoV-2, generated after infection or vaccination.
methodsWe studied antibody titers, neutralizing antibodies and cellular immune responses to four different COVID-19 vaccines, namely Pfizer-BioNTech, Moderna Spikevax, AstraZeneca and Sinopharm vaccines in the Bangladeshi population (
resultsmRNA vaccines Moderna (14,655 ± 11.3) and Pfizer (13,772 ± 11.5) elicited significantly higher anti-Spike (S) antibody titers compared to the Adenovector vaccine AstraZeneca (2443 ± 12.8) and inactivated vaccine Sinopharm (1150 ± 11.2). SARS-CoV-2-specific neutralizing antibodies as well as IFN-γ-secreting lymphocytes were more abundant in Pfizer and Moderna vaccine recipients compared to AstraZeneca and Sinopharm vaccine recipients. Participants previously infected with SARS-CoV-2 exhibited higher post-vaccine immune responses (S-specific and neutralizing antibodies, IFN-γ-secreting cells) compared to uninfected participants. Memory B (B
conclusionsmRNA vaccines generated a higher antibody response, while a differential cellular response was observed for different vaccine types, suggesting that both cellular and humoral responses are important in immune monitoring of different types of vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.